Cargando…

APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response

APOBEC enzymes are responsible for a mutation signature (TCW>T/G) implicated in a wide variety of tumors. We explore the APOBEC mutational signature in bladder cancer and the relationship with specific mutations, molecular subtype, gene expression, and survival using sequencing data from The Canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glaser, Alexander P., Fantini, Damiano, Wang, Yiduo, Yu, Yanni, Rimar, Kalen J., Podojil, Joseph R., Miller, Stephen D., Meeks, Joshua J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796993/ https://www.ncbi.nlm.nih.gov/pubmed/29435122 http://dx.doi.org/10.18632/oncotarget.23344

Ejemplares similares

Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma
por: Podojil, Joseph R., et al.
Publicado: (2020)

FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis
por: Waters, Catherine E., et al.
Publicado: (2014)

Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma
por: Piunti, Andrea, et al.
Publicado: (2022)

Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer
por: Rimar, Kalen J., et al.
Publicado: (2018)

MutSignatures: an R package for extraction and analysis of cancer mutational signatures
por: Fantini, Damiano, et al.
Publicado: (2020)

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
por: Boichard, Amélie, et al.
Publicado: (2018)

A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer
por: Fantini, Damiano, et al.
Publicado: (2018)

Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B
por: Shi, K., et al.
Publicado: (2016)

APOBEC3A/B-induced mutagenesis is responsible for 20% of heritable mutations in the TpCpW context
por: Seplyarskiy, Vladimir B., et al.
Publicado: (2017)

APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer
por: Natesan, Divya, et al.
Publicado: (2022)

Mechanisms of APOBEC3 mutagenesis in human cancer cells
por: Petljak, Mia, et al.
Publicado: (2022)

Genetic inhibitors of APOBEC3B-induced mutagenesis
por: Mertz, Tony M., et al.
Publicado: (2023)

The BBN model: a mouse bladder cancer model featuring basal-subtype gene expression and MLL3/MLL4 genetic disruption
por: Fantini, Damiano, et al.
Publicado: (2018)

Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA
por: Bergstrom, Erik N., et al.
Publicado: (2022)

Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis
por: Petljak, Mia, et al.
Publicado: (2019)

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers
por: Chan, Kin, et al.
Publicado: (2015)

PrimPol prevents APOBEC/AID family mediated DNA mutagenesis
por: Pilzecker, Bas, et al.
Publicado: (2016)

Analysis of gene expression and mutation data points on contribution of transcription to the mutagenesis by APOBEC enzymes
por: Chervova, Almira, et al.
Publicado: (2021)

APOBEC mutagenesis is a common process in normal human small intestine
por: Wang, Yichen, et al.
Publicado: (2023)

Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution
por: Venkatesan, S, et al.
Publicado: (2018)

APOBEC3B and CD274 as Combined Biomarkers for Predicting Response to Immunotherapy in Urothelial Carcinoma of the Bladder
por: Zhang, Chuanhao, et al.
Publicado: (2022)

APOBEC3B, a molecular driver of mutagenesis in human cancers
por: Zou, Jun, et al.
Publicado: (2017)

APOBEC mutagenesis is low in most types of non-B DNA structures
por: Ponomarev, Gennady V., et al.
Publicado: (2022)

APOBEC3B regulates R-loops and promotes transcription-associated mutagenesis in cancer
por: McCann, Jennifer L., et al.
Publicado: (2023)

DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer
por: Kanu, Nnennaya, et al.
Publicado: (2016)

Potential Utilization of APOBEC3-Mediated Mutagenesis for an HIV-1 Functional Cure
por: Ikeda, Terumasa, et al.
Publicado: (2021)

Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers
por: DeWeerd, Rachel A., et al.
Publicado: (2022)

APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential
por: Butler, Kelly, et al.
Publicado: (2023)

APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression
por: Yamazaki, Hiroyuki, et al.
Publicado: (2020)

Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer
por: Harris, Reuben S
Publicado: (2015)

Comprehensive Analyses Reveal Effects on Tumor Immune Infiltration and Immunotherapy Response of APOBEC Mutagenesis and Its Molecular Mechanisms in Esophageal Squamous Cell Carcinoma
por: Yang, Jie, et al.
Publicado: (2023)

Enzyme cycling contributes to efficient induction of genome mutagenesis by the cytidine deaminase APOBEC3B
por: Adolph, Madison B, et al.
Publicado: (2017)

Enzyme cycling contributes to efficient induction of genome mutagenesis by the cytidine deaminase APOBEC3B
por: Adolph, Madison B, et al.
Publicado: (2018)

Efficient collection of a large number of mutations by mutagenesis of DNA damage response defective animals
por: Suehiro, Yuji, et al.
Publicado: (2021)

APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
por: Wang, Shixiang, et al.
Publicado: (2018)

Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
por: Li, Xiaoling, et al.
Publicado: (2023)

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer
por: Olah, Csilla, et al.
Publicado: (2022)

Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis
por: Lavens, Delphine, et al.
Publicado: (2010)

Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis
por: Lavens, Delphine, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_q87030cfb11j840vb8cagjlvnb